A clinical study on regional lymphatic chemotherapy using an activated carbon nanoparticle-chemotherapy drugs in patients with esophageal cancer

A clinical study on regional lymphatic chemotherapy using an activated carbon nanoparticle–paclitaxel in patients with esophageal cancer

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-IIR-16008115

Enrollment

Unknown

Registered

2016-03-17

Start date

2016-03-19

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

esophageal cancer

Interventions

Lymphatic chemotherapy:intraoperative chemotherapy with activated carbon nanoparticle–paclitaxel

Paclitaxel:intraoperative chemotherapy with paclitaxel

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. There is no other organ metastasis or distant lymph node metastasis; 2. Without previous chemotherapy or radiation therapy, white blood cell count greater than 4000/ul and platelet count greater than 100,000/ul, no abnormality of cardiac, renal or liver function; 3. patients volunteer to participate,and signed informed consent.

Exclusion criteria

Exclusion criteria: 1. Be allergy to test drugs or paclitaxel; 2. With a history of alcoholism, drug abuse or drug abuse; 3. Participated in any drug test in the 3 months ago before the trial.

Design outcomes

Primary

Measure	Time frame
Drug concentration;	—

Secondary

Measure	Time frame
Situation of lymph node dissection;2 year survival rate;5 year survival rate;	—

Countries

China

Contacts

Public ContactCHEN Long-qi

Department of Thoracic Surgery, West China Hospital of Sichuan University

drchenlq@gmail.com+86 18980601850

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026